Theravance Biopharma Announces First Patient Dosed in Phase 2b/3 Study of TD-1473 in Patients with Ulcerative Colitis
DUBLIN, March 12, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the...
Health News 2 me
healthnews2me.com
Tag: 2b/3
Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata
January 3, 2019 -- Pfizer Inc. (NYSE: PFE) announced today the initiation of a Phase...